Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alteon (ALT) -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (295)	11/29/2000 4:03:31 PM
From: tnsaf	Read Replies (1) \| Respond to of 318

Wednesday November 29, 10:23 am Eastern Time Press Release SOURCE: BioStratum Incorporated BioStratum Signs Agreement With Shire for Pyridorin(TM)XR RESEARCH TRIANGLE PARK, N.C., Nov. 29 /PRNewswire/ -- BioStratum Incorporated has signed a Development and License Agreement with Shire Laboratories Incorporated to develop an extended release (XR) version of BioStratum's lead drug candidate, Pyridorin(TM). Currently in Phase II clinical trials, Pyridorin(TM) treats diabetic kidney disease. ``Formulating Pyridorin(TM) into a single daily dosage will be more convenient for a patient and has the added clinical benefit of assuring a stable plasma concentration of Pyridorin(TM),'' said Dr. Claus Kuhl, president and chief executive officer of BioStratum. He added, ``This agreement is intended to ensure that we have an extended release version of Pyridorin(TM) in time for our Phase III clinical trials.'' The application of our expertise in drug delivery to this exciting new drug is an innovative way to modify the pharmacokinetic characteristics of Pyridorin(TM),`` said Jack Khattar, president and chief executive officer of Shire Laboratories. ''Our leadership in oral controlled release drug delivery provides BioStratum with access to multiple technologies which will be exploited to address the product's objectives,`` he added. Pyridorin(TM) is BioStratum's lead drug and a result of BioStratum's leadership position in research and development related to the body's basal lamina. In animal models of diabetic nephropathy, Pyridorin(TM) has been shown to inhibit the formation of advanced glycation end products (A.G.E.s) which are believed to damage the kidney function and ultimately lead to kidney failure.